Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)
The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients... Continue Reading
The Oncotype DX® Recurrence Score® result is a robust predictor of loco-regional recurrence in node-positive, estrogen receptor (ER)-positive patients treated with adjuvant hormonal therapy and chemotherapy,... Continue Reading
Exposure to ionizing radiation during radiation therapy for breast cancer may increase the risk of heart attack or heart disease later in life, according to the results of a study published in the New... Continue Reading
The prognosis of triple-negative breast cancer (TNBC) tends to be better among older women than among younger women, even though older women are less likely to receive aggressive treatment. These results... Continue Reading
In a Phase II clinical trial, an anti-copper drug has shown promising results against triple-negative breast cancer. These results were published in the Annals of Oncology. Studies have suggested that... Continue Reading
There has been a dramatic increase in the number of women undergoing immediate breast reconstruction after mastectomy—and this increase correlates with an increase in the use of implants, according to... Continue Reading
Women with estrogen receptor-positive (ER-positive) breast cancer who take adjuvant tamoxifen for 10 years experience greater protection from late recurrence and death from breast cancer compared to those... Continue Reading
Brachytherapy is tied to more wound and skin complications than the standard radiation technique, according to the results of a study published in the Journal of Clinical Oncology. For women with early-stage... Continue Reading
One year of therapy with Herceptin® (trastuzumab) appears to be optimal in the adjuvant setting for women diagnosed with HER2-positive early breast cancer, according to the results of two studies presented... Continue Reading
Among women with node-positive, estrogen receptor-positive breast cancer, the Oncotype DX test provides information about expected recurrence risk and survival after treatment with chemotherapy and hormone... Continue Reading